



(11) **EP 3 630 754 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
31.08.2022 Bulletin 2022/35

(45) Date of publication and mention
of the grant of the patent:
27.07.2022 Bulletin 2022/30

(21) Application number: **18728875.8**

(22) Date of filing: **01.06.2018**

(51) International Patent Classification (IPC):
C07D 417/12 ^(2006.01) **C07D 417/14** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 31/427** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 417/12; C07D 417/14

(86) International application number:
PCT/EP2018/064399

(87) International publication number:
WO 2018/220149 (06.12.2018 Gazette 2018/49)

(54) **ISOINDOLINE-ACETYLENE COMPOUNDS FOR THE TREATMENT OF CANCER**
ISOINDOLINE-ACETYLEN VERBINDUNGEN ZUR BEHANDLUNG VON KREBS
COMPOSES D'ISOINDOLINE-ACETYLENE POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Validation States:
MA

(30) Priority: **02.06.2017 EP 17174334**
02.06.2017 US 201762514244 P
10.08.2017 US 201762543438 P

(43) Date of publication of application:
08.04.2020 Bulletin 2020/15

(73) Proprietor: **F. Hoffmann-La Roche AG**
4070 Basel (CH)

(72) Inventors:
• **JAESCHKE, Georg**
4070 Basel (CH)
• **RICCI, Antonio**
4070 Basel (CH)

- **RUEHER, Daniel**
4070 Basel (CH)
- **STEINER, Sandra**
4070 Basel (CH)
- **DUPLESSIS, Martin**
Watertown
MA 02472 (US)
- **NAGEL, Yvonne Alice**
4070 Basel (CH)
- **KUHN, Bernd**
4070 Basel (CH)

(74) Representative: **Pomeranc, Didier**
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel (CH)

(56) References cited:
WO-A1-2009/158369 WO-A1-2016/183534

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).